Intravenous ascorbic acid protocol for cancer patients: Scientific rationale, pharmacology, and clinical experience

Functional Foods in Health and Disease

Volumn 3, Issue 8, 2013, Pages 344-366

  Mikirova, N A ^a   Casciari, J J ^a   Hunninghake, R E ^a   Riordan, N H ^a  

^a Riordan Clinic   (United States)

Author keywords

C reactive protein; Cancer; High dose Vitamin C; Inflammation; Inflammatory cytokines

Indexed keywords

EID: 84890206489     PISSN: 23787007     EISSN: 21603855     Source Type: Journal    
DOI: 10.31989/ffhd.v3i8.43     Document Type: Review

References (68)

1. Hoffman F. Micronutrient requirements of cancer patients. Cancer 1985; 55(Supl.1): 145-50.
2. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer, a review. Cancer Res 1979; 39: 663-681.
3. Geeraert L. Intravenous high-dose vitamin C. CAM-Cancer Consortium 2012. [Online] Available at: http://www.cam-cancer.ort/CAM-Summaries/Other-CAM/Intravenous-highdose-vitamin-C
4. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, Gonzalez MJ, Miranda-Massari JR, Mora EM, Rosario N Rivera A. Intravenous Ascorbic Acid: Protocol for its Application and Use. P R Health Sci J 2003; 22: 225-32.
5. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS ONE 2010; 5(7): 11414.
6. Ayami Furuya, Misao Uozuki, Hisashi Yamasaki, Tsutomu Arakawa, Mikio Ariata, A. Hajime. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. International journal of molecular medicine 22: 541-545, 2008.
7. Mikirova N, Casciari J, Riordan N. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenesis Res 2012; 2: 2-6.
8. McCormick, W. Cancer: a collagen disease, secondary to nutrition deficiency. Arch. Pediatr 1959; 76: 166-171.
9. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005; 24:269-276.
10. Henson D, Block G, Levine M. Ascorbic acid: biological functions and relation to cancer. JNCI 1991; 83: 547-50.
11. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS USA 1976; 73: 3685-9.
12. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301: 687-90.
13. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double- blind comparison. N Engl J Med 1985; 312: 137-41.
14. Hornig D. Distribution of ascorbic acid metabolites and analogues in man and animals. Ann NY Acad Sci 1975;258: 103-18.
15. Keith M, Pelletier O. Ascorbic acid concentrations in leukocytes and selected organs of guinea pigs in response to increasing ascorbic acid intake. Am J Clin Nutr 1974; (27): 368-72.
16. Ginter E, Bobeck P, Vargova D. Tissue levels and optimal dosage of vitamin C in guinea pigs. Nutr Metab1979; (27):217-26.
17. Levine M, Conry-Cantilena C, Yang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS USA1996;(93): 3704-9.
18. Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. Palliat Med 2005; 19:17-20.
19. Casciari JJ, Riordan NH, Schmidt TS, Meng XL, Jackson JA, Riordan HD. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fiber in vitro tumors. Br J Cancer 2001; 84: 1544-1550.
20. Padayatti SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140: 533-537.
21. Riordan NH, Rioredan HD, Casciari JJ. Clinical and experimental experiences with intravenous vitamin C. Journal of Orthomolecular medicine, 2000, 15, 201-213.
22. Mikirova N, Casciari J, Hunninghake R, Riordan N. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. Journal of translational medicine, 2013, 11 (in press).
23. Benade L, Howard, T, Burk, D., 1969. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. Oncology 1969; (23): 33-43.
24. Riordan NH, Riordan HRD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical hypothesis 1995; 44:207-213.
25. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl Acad. Sci. U. S. A. 2005; 102:13604-13609.
26. Frei B, Lawson S. Vitamin C and cancer revisited. PNAC USA 2008; 105: 11037-8.
27. Verrax J, Cadrobbi J, Marques C, Taper H, Habraken Y, Piette J, Calderon PB. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic capsase-3 independent form of cell death. Apoptosis 2004; 9: 223-33.
28. Gonzalez M, Mora EM, Miranda-Massari JR, Matta J, Riordan HD, Riordan NH. Inhibition of human breast cancer carcinoma cell proliferation by ascorbate and copper. PRHSJ 2002; 21: 21-3.
29. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl Acad. Sci. U. S. A. 2008; 105:11105-11109.
30. Verrax J, Calderon P. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009; 47:32-40.
31. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 2010; 16:509-520.
32. Belin S, Kaya F, Duisit G, Giacomett S, Ciccoloni J, Fortes M. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS ONE 2009; 4(2):E44-0.
33. Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Lee S. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009; 7: 70.
34. Pollard H, Levine M, Eidelman O, Pollard M. Pharmacological ascorbic acid supresses syngenic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 2010; 24(3): 249-55.
35. Casciari JJ, Riordan HD, Miranda-Massari JR, Gonzalez MJ. Effect of high dose ascorbate administration on L-10 tumor grows in guinea pigs. PRHSJ, 2005, 24, 145-150.
36. Ashino H, Shimamura M, Nakajima M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis 2003; 6:259-269.
37. Page EL, Chan DA, Giaccia AJ, Levine M, Richard DE. Hypoxia-inducible factor-1 (alpha) stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2007; 19:86-94.
38. Mikirova N, Ichim T, Riordan N. Anti-angiogenic effect of high doses of ascorbic acid. Journal of Translational Medicine 2008; 6:50.
39. Mikirova Nina, Casciari Joseph, Taylor Paul, Rogers Andrea, Effect of high-dose intravenous vitamin C on inflammation in cancer patients. Journal of Translational Medicine.2012, 10:189.
40. St. Sauver JL, Sarma AV, McGree DJ, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ. Associations betweeen c-reactive protein and benigh prosaic hyperplasia lower urinary tract outcomes in a population based cohort. Am J Epidemiol 2009; 169: 1281-90.
41. Lin A, Chen K, Chung H, Chang S. The significance of plasma c-reactive protein in patients with elevated serum prostate-specific antigen levels. Urological Sci 2010; 21: 88-92.
42. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 1999; 59(18):4555-8.
43. Raloff J. Antioxidants may help cancers thrive. Science News 2000; 157: 5.
44. Heaney ML, Gardner JR, KarasawasN, Golde DW, Scheinberg DA, Smith EA, O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Research 2008; 68: 8031-8038.
45. Espey M, Chen Q, Levine M. Comment re: vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Research 2009; 69:8830.
46. Fujita K, Shinpo K, Yamada K, Sato K, Niimi H, Shamoto M, Nagatsu T, Takeuchi T, Umezawa H. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 1982; 309-16: 42.
47. Okunieff P, Suit H. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine firbosarcomas. JNCI 1987; 79: 377-81
48. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996; 103: 183-9.
49. Taper H, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 1996; 16: 499-503.
50. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells toward cytostatic drugs. Cancer Chemother Pharmacol 2011; 67: 1157-66.
51. Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, Nakayama E. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Ratiat Res 2011; 52: 229-237.
52. Espey M, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 2011; 50: 1610-1619.
53. Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not inferfere with chemotherapy or radiation therapy and can increase survival, part 1. Atlern Ther Health Med 2007; 13: 22-28.
54. Block K, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementaion on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123: 1227-39.
55. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Res Suppl 1982; 23: 103-13.
56. Jackson J, Riordan H, Hunninghauke R, Riordan N. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med 1995; 10:87-88.
57. Riordan H, Jackson J, Riordan N, Schultz M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Ortho Med 1998; 13:72-73.
58. Riordan N, Jackson J, Riordan H. Intravenous vitamin C in a terminal cancer patient. J Ortho Med 1996; 11:80-82.
59. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenous vitamin C as a cancer therapy: three cases. CMAJ 2006; 174(7):937-42.
60. Drisko J, Chapman J, Hunter V. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr 2003; 22:118-23.
61. Yeom C, Jung G, Song K. Changes of terminal cancer patietns health related qualtiy of life after high dose vitamin C administration. Korean Med Sci 2007; 22: 7-11.
62. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Vollbracht, C. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 2011; 82:983-90.
63. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19(12)-2095
64. Monti D, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012; 7: e29794.
65. Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J. Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med 1994; 24: 410-411.
66. Campbell A, Jack T. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J 1979; 24: 151.
67. Rivers J. Safety of high-level vitamin C ingestion. In: Third Conference on Ascorbic Acid. Ann NY Acad Sci 1987; 489: 95-102.
68. Jackson J, Hunninghake R. False positive blood glucose readings after high-dose intravenous vitamin C. J Ortho Med 2006; 21: 188-90.